Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Helix Acquisition Corp. II Class A ( (HLXB) ) just unveiled an announcement.
On July 11, 2025, Helix Acquisition Corp. II and BridgeBio Oncology Therapeutics announced that their registration statement for a business combination has been declared effective by the SEC. The extraordinary general meeting of Helix shareholders to approve the merger is scheduled for August 4, 2025, with the transaction expected to close later that month, potentially impacting the companies’ market positioning and stakeholder interests.
More about Helix Acquisition Corp. II Class A
BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics targeting RAS and PI3Kα malignancies. Helix Acquisition Corp. II is a special purpose acquisition company formed to facilitate mergers or similar business combinations.
Average Trading Volume: 44,543
Technical Sentiment Signal: Buy
See more insights into HLXB stock on TipRanks’ Stock Analysis page.